Ibrutinib, a first-generation oral small molecule, is a selective inhibitor of Bruton's Tyrosine Kinase (BTK), a critical component of the B cell receptor (BCR) pathway in B cell lymphomas. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.